Company Overview of Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. discovers and develops potential drugs for the treatment of breathing-control conditions associated with surgical anesthesia, drug-induced respiratory depression, pain management, and sleep apnea. It focuses on respiratory depression in the acute care market and sleep apnea in the chronic care market; and ventilator weaning, anesthetic/analgesic-induced respiratory depression, COPD, obesity-hypoventilation syndrome, and other diseases. The company was incorporated in 2003 and is based in Horsham, Pennsylvania.
213 Witmer Road
Horsham, PA 19044
Founded in 2003
Key Executives for Galleon Pharmaceuticals, Inc.
Founder, Chief Executive Officer and President
Chief Technology Officer and Vice President of Chemistry
Head of Bioanalytical Chemistry & DMPK
Senior Vice President of Drug Discovery
Compensation as of Fiscal Year 2014.
Galleon Pharmaceuticals, Inc. Key Developments
Galleon Pharmaceuticals Announces Publication of Proof-of- Concept Clinical Studies for GAL-021, Projected Use for the Emerging Perioperative Sleep Apnea Epidemic
Sep 2 14
Galleon Pharmaceuticals announced clinically and statistically significant (p<0.01) results from a double-blind, placebo-controlled clinical proof-of-concept study of its lead investigational compound GAL-021 in normal volunteers. The data were published in the most recent issue of Anesthesiology. The study sought to assess whether GAL-021 stimulated breathing in humans with respiratory depression induced by a potent opioid under conditions common after surgery. Researchers concluded that GAL-021 met or exceeded the study's pre-defined goals of maintaining both respiration and pain control under these conditions, and called for further clinical exploration of the drug's safety and efficacy. GAL-021 is being developed to prevent respiratory complications in surgical patients, including those at higher risk due to sleep apnea. According to a recent report in the New England Journal of Medicine, 25% to 80% of surgical patients have sleep apnea predisposing them to the rapidly emerging perioperative sleep apnea epidemic. The combination of sleep apnea with respiratory depressant drugs such as opioids, sedatives and anesthetics is especially dangerous and complicates care of these patients.
Galleon Pharmaceuticals Demonstrates Successful Clinical Proof-of-Concept for Lead Product from Sleep Apnea Drug-Discovery Platform
Apr 11 13
Galleon Pharmaceuticals announced a clinically significant outcome in a clinical proof-of-concept study evaluating the ability of its lead investigational drug, GAL-021, to successfully regulate respiratory drive, a key requirement to prevent respiratory complications in high-risk surgical patients. This is the first time a drug has been shown to regulate and protect respiratory drive from drug-induced respiratory depression. In this study, intravenous GAL-021 was able to reverse respiratory depression under challenging conditions including high doses of opioids and elevated carbon-dioxide levels, which can be particularly problematic for post-surgical and sleep apnea patients. The company is actively seeking funding to advance this promising candidate into a broad Phase II program. In the double-blinded, placebo-controlled crossover study, 12 people with both normal and elevated carbon-dioxide levels were given alfentanil, a potent opioid analgesic drug commonly used during surgery. Then two dose-levels of alfentanil and two dose-levels of GAL-021 were administered. In this study, GAL-021 successfully protected against the opioid-induced respiratory depression while not affecting analgesia. The dose-dependent protective effect of GAL-021 was statistically and clinically significant at both low and high doses of alfentanil. GAL-021 was well-tolerated with side effects that did not differ from placebo.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries